Anglais

Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.

6 Formulaires  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    3. Subject ID, family ID, father and mother IDs, and sex of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    4. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    5. Subject ID, age, height, weight, tumor grade, tumor stage, histology of tumor, tumor ER, HER2, and PR status, menopause status, tumor progression and death of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    6. Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
pht003004
Description

pht003004

GENEVA ID
Description

SUBJID

Type de données

text

Alias
UMLS CUI [1,1]
C2348585
Consent group as determined by DAC
Description

CONSENT

Type de données

text

Alias
UMLS CUI [1,1]
C1257890
UMLS CUI [1,2]
C0021430
Source repository where subjects originate
Description

SUBJ_SOURCE

Type de données

string

Alias
UMLS CUI [1,1]
C0449416
UMLS CUI [1,2]
C3847505
Subject ID used in the Source Repository
Description

SOURCE_SUBJID

Type de données

string

Alias
UMLS CUI [1,1]
C2348585
UMLS CUI [1,2]
C0449416
UMLS CUI [1,3]
C3847505
Retour au début de la page

Similar models

Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.

6 Formulaires
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    3. Subject ID, family ID, father and mother IDs, and sex of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    4. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    5. Subject ID, age, height, weight, tumor grade, tumor stage, histology of tumor, tumor ER, HER2, and PR status, menopause status, tumor progression and death of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    6. Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
pht003004
SUBJID
Item
GENEVA ID
text
C2348585 (UMLS CUI [1,1])
Item
Consent group as determined by DAC
text
C1257890 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
CONSENT
Code List
Consent group as determined by DAC
CL Item
Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects (0)
CL Item
Breast cancer, study drug efficacy and toxicity, and covariates (BCETC) (1)
SUBJ_SOURCE
Item
Source repository where subjects originate
string
C0449416 (UMLS CUI [1,1])
C3847505 (UMLS CUI [1,2])
SOURCE_SUBJID
Item
Subject ID used in the Source Repository
string
C2348585 (UMLS CUI [1,1])
C0449416 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,3])
Retour au début de la page